BioStem Technologies, Inc. Common Stock (BSEM) Stock Price

BSEMStock

$2.09−55.61%52W

Market Cap$39.02M

P/E—

PEG Ratio—

Div yield—

Beta0.58

BSEM Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-66.88%

Price vs S&P 500 (4W)-51.17%

VGM Score52.67

P/CF (Annual)3.93x

Book Value / Share (Quarterly)$1.88

P/TBV (Annual)1.60x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)122.00%

Cash Flow / Share (Quarterly)$0.11

Price vs S&P 500 (YTD)-57.07%

Gross Margin (TTM)93.53%

Net Profit Margin (TTM)-13.08%

EPS (TTM)$-1.20

10-Day Avg Trading Volume0.10M

EPS Excl Extra (TTM)$-1.20

Revenue Growth (5Y)170.15%

EPS (Annual)$-0.39

ROI (Annual)-15.62%

Gross Margin (Annual)93.59%

Net Profit Margin (5Y Avg)-36.17%

Cash / Share (Quarterly)$0.81

Revenue Growth QoQ (YoY)-91.54%

ROA (Last FY)-13.15%

EBITD / Share (TTM)$-0.77

ROE (5Y Avg)-174.94%

Operating Margin (TTM)-11.11%

Cash Flow / Share (Annual)$0.39

P/B Ratio1.22x

P/B Ratio (Quarterly)2.13x

EV / Revenue (TTM)0.43x

Net Interest Coverage (TTM)50.05x

ROA (TTM)-28.39%

EV / EBITDA (TTM)1.84x

EPS Incl Extra (Annual)$-0.39

Current Ratio (Annual)4.12x

Quick Ratio (Quarterly)0.86x

3-Month Avg Trading Volume0.10M

52-Week Price Return-55.61%

EV / Free Cash Flow (Annual)4.30x

Tangible BV / Share (Quarterly)$0.59

P/S Ratio (Annual)0.82x

Asset Turnover (Annual)0.95x

52-Week High$8.40

Operating Margin (5Y Avg)-25.84%

EPS Excl Extra (Annual)$-0.39

CapEx CAGR (5Y)83.75%

26-Week Price Return-56.98%

Quick Ratio (Annual)3.66x

13-Week Price Return-44.56%

Total Debt / Equity (Annual)0.08x

Current Ratio (Quarterly)1.14x

Enterprise Value$28.32M

Revenue / Share Growth (5Y)105.00%

Asset Turnover (TTM)0.86x

Inventory Turnover (Annual)1.29x

Pretax Margin (Annual)-0.82%

Cash / Share (Annual)$1.76

3-Month Return Std Dev109.55%

Gross Margin (5Y Avg)63.83%

ROE (Last FY)-16.81%

Net Interest Coverage (Annual)60.92x

EPS Basic Excl Extra (Annual)$-0.39

P/FCF (TTM)3.43x

Receivables Turnover (TTM)-0.33x

EV / Free Cash Flow (TTM)15.29x

Total Debt / Equity (Quarterly)0.09x

EPS Incl Extra (TTM)$-1.20

Receivables Turnover (Annual)2.88x

ROI (TTM)-43.88%

Pretax Margin (5Y Avg)-33.62%

Revenue / Share (Annual)$2.84

Tangible BV / Share (Annual)$2.32

Price vs S&P 500 (52W)-71.14%

Year-to-Date Return-45.14%

5-Day Price Return-14.34%

EPS Normalized (Annual)$-0.39

ROA (5Y Avg)-31.54%

Net Profit Margin (Annual)-13.86%

Month-to-Date Return-32.36%

EBITD / Share (Annual)$-0.03

Operating Margin (Annual)-1.45%

LT Debt / Equity (Annual)0.00x

P/CF (TTM)7.73x

ROI (5Y Avg)-78.98%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.20

P/TBV (Quarterly)6.81x

P/B Ratio (Annual)1.59x

Inventory Turnover (TTM)1.41x

Pretax Margin (TTM)-10.88%

Book Value / Share (Annual)$2.33

Price vs S&P 500 (13W)-47.25%

Beta0.58x

P/FCF (Annual)5.92x

Revenue / Share (TTM)$-1.12

ROE (TTM)-47.03%

52-Week Low$1.88

vGradeA

gGradeC

mGradeD

vgmGradeC

BSEM Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 12, 2026	-$0.50	-$0.52	-4.00%(-$0.02)
Q1 2026	May 14, 2026	-$0.28	-$0.52	-85.71%(-$0.24)
Q3 2025	Nov 13, 2025	$0.00	$0.06	+0.00%(+$0.06)
Q2 2025	Aug 14, 2025	$0.32	$0.11	-66.88%(-$0.21)

BSEM Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.14

Industry Peers — Biological Products(186)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
BSEMBioStem Technologies, Inc. Common Stock	A	C	D	—	—	93.5%	—	$2.09
AMGNAmgen Inc	D	C	A	6.1x	9.1%	74.3%	2.9%	$432.49
GILDGilead Sciences Inc	C	B	A	6.4x	5.5%	79.6%	133.6%	$156.19
MRNAModerna, Inc. Common Stock	F	C	A	39.1x	-27.6%	36.4%	—	$218.01
ARGXargenx SE American Depositary Shares	D	A	B	6.6x	165.2%	89.8%	—	$819.14
RVMDRevolution Medicines, Inc. Common Stock	F	—	B	3296.2x	—	—	—	$177.96
BIIBBiogen Inc. Common Stock	C	D	A	3.4x	0.3%	74.0%	-18.8%	$232.65
BNTXBioNTech SE American Depositary Share	C	C	C	7.6x	-11.8%	79.2%	—	$87.71
EXELExelixis Inc	C	B	A	6.3x	9.2%	96.5%	31.1%	$62.23
HALOHalozyme Therapeutics, Inc.	D	B	A	8.3x	41.1%	82.4%	22.9%	$121.84
NBIXNeurocrine Biosciences Inc	C	B	B	4.1x	34.4%	98.0%	2.3%	$135.71
TECHBio-Techne Corp.	D	C	B	9.4x	-0.4%	66.2%	6.0%	$72.57
RGENRepligen Corp	F	C	A	14.2x	16.5%	53.8%	-4.9%	$175.42
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	—	—	—	—	$135.07
PCVXVaxcyte, Inc. Common Stock	—	—	B	—	—	—	—	$63.62
IBRXImmunityBio, Inc. Common Stock	F	A	A	58.7x	192.9%	99.3%	—	$9.18
QGENQIAGEN N.V.	C	C	B	4.5x	3.0%	62.5%	4.2%	$46.13
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	21.3x	22.6%	94.6%	—	$316.58
TWSTTwist Bioscience Corporation Common Stock	D	B	A	20.2x	19.2%	52.0%	—	$132.75
KYMRKymera Therapeutics, Inc. Common Stock	F	B	B	83.0x	134.8%	—	—	$104.78
IOVAIovance Biotherapeutics, Inc. Common Stock	D	B	A	19.0x	34.5%	48.4%	—	$13.62
IMVTImmunovant, Inc. Common Stock	—	—	C	—	—	—	—	$26.73
KODKodiak Sciences Inc Common Stock	—	—	A	—	—	—	—	$85.75
CGONCG Oncology, Inc. Common stock	F	A	B	851.8x	1030.3%	-85.2%	—	$59.85
SRRKScholar Rock Holding Corporation Common Stock	F	—	C	102.7x	—	—	—	$39.90
CRSPCRISPR Therapeutics AG	D	B	B	355.6x	-64.8%	—	—	$49.25
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	B	12.4x	50.1%	75.6%	—	$24.02
RLAYRelay Therapeutics, Inc. Common Stock	F	D	B	344.7x	23.9%	—	—	$16.28
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	5.5x	105.2%	93.3%	—	$68.07
DNLIDenali Therapeutics Inc. Common Stock	F	—	C	781.1x	—	—	—	$17.61
BEAMBeam Therapeutics Inc. Common Stock	D	B	C	15.5x	158.9%	—	—	$23.47
ADMAADMA Biologics, Inc.	C	C	B	4.7x	8.0%	64.7%	—	$10.68
VCELVericel Corporation	D	B	B	6.7x	22.9%	74.6%	38.9%	$40.13
BCRXBioCryst Pharmaceuticals Inc	B	A	B	2.1x	68.7%	97.8%	—	$7.79
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	33.9x	-15.1%	3.5%	—	$3.46
NVAXNovavax Inc	C	D	B	4.5x	-61.6%	79.2%	—	$11.26
ALVOAlvotech Ordinary Shares	D	D	B	3.9x	-12.1%	60.7%	—	$5.00
MESOMesoblast Limited American Depositary Shares	D	A	C	14.6x	599.2%	86.1%	—	$13.28
VIRVir Biotechnology, Inc. Common Stock	B	B	B	5.6x	1496.1%	100.0%	—	$9.96
MAZEMaze Therapeutics, Inc. Common Stock	—	A	B	—	700.0%	—	—	$27.53
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	3.5x	20.9%	98.9%	—	$29.40
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	C	—	—	—	—	$30.07
INBXInhibrx Biosciences, Inc. Common Stock	D	C	A	944.3x	550.0%	—	—	$89.83
TSHATaysha Gene Therapies, Inc. Common Stock	D	C	D	120.7x	-32.3%	—	—	$3.62
IMTXImmatics N.V. Ordinary Shares	C	C	C	21.5x	-68.0%	—	—	$6.73
REPLReplimune Group, Inc.	—	—	B	—	—	—	—	$10.86
VORVor Biopharma Inc. Common Stock	—	—	C	—	—	—	—	$18.03
MGTXMeiraGTx Holdings plc Ordinary Shares	C	A	C	2.2x	948.4%	98.0%	—	$9.28
SLBTSL Science Holding Limited Ordinary Shares	—	—	D	—	—	—	—	$1.53
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	C	—	—	—	—	$12.93
GLUEMonte Rosa Therapeutics, Inc. Common Stock	D	F	D	28.9x	-83.9%	—	—	$9.74

About BioStem Technologies, Inc. Common Stock

BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. The company develops, manufactures, and sells tissue allografts for the wound care market with a focus on the treatment of diabetic, pressure, and venous ulcers. Utilizing its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE AC, AmnioWrap2, and Others. The company generates key revenue from VENDAJE AC.